Characterisation of the gene encoding type II DNA topoisomerase from Leishmania donovani: a key molecular target in antileishmanial therapy
about
Characterization of the DNA-binding domain and identification of the active site residue in the 'Gyr A' half of Leishmania donovani topoisomerase IIEvidence for rosettes as an unrecognized stage in the life cycle of Leishmania parasites.Leishmania actin binds and nicks kDNA as well as inhibits decatenation activity of type II topoisomerasePromising therapeutic targets for antileishmanial drugs.An unusual type IB topoisomerase from African trypanosomes.Cloning, functional analysis and post-transcriptional regulation of a type II DNA topoisomerase from Leishmania infantum. A new potential target for anti-parasite drugs.Topoisomerases of kinetoplastid parasites: why so fascinating?Drug targets in Leishmania.Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discoveryFunctional dissection of the C-terminal domain of type II DNA topoisomerase from the kinetoplastid hemoflagellate Leishmania donovani.Hypothesis: The potential application of doxorubicin against cutaneous leishmaniasis.Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani.Distinct genes encode type II Topoisomerases for the nucleus and mitochondrion in the protozoan parasite Trypanosoma brucei.Mitochondrial and nuclear localization of topoisomerase II in the flagellate Bodo saltans (Kinetoplastida), a species with non-catenated kinetoplast DNA.Isobenzofuranone derivative JVPH3, an inhibitor of L. donovani topoisomerase II, disrupts mitochondrial architecture in trypanosomatid parasites
P2860
Q24793787-C6D00BEF-2292-48B5-B8A2-4676CFFBDD05Q30500043-60928D47-373E-42E4-ADD3-842668F6BC26Q33889361-7E2849FA-0114-4F88-98A6-C0DBB3397113Q34837180-E65FB0EA-A5F4-411F-ABE5-B2ED1CA912A9Q35146022-F2C58335-E0F5-4793-AFD6-21CD8F48839AQ35222665-123FDDC2-8BC5-4A4E-9E88-2CF57D2D41F7Q36624125-9A283FEE-9072-43E1-A3C9-2FA6D784CC08Q37869809-5BAAD14B-3C2B-4AF6-9016-9AAF213FFE3BQ38291539-9FBEE02E-21B9-415C-A2D4-FE532831BFE1Q39922598-3A0B53BA-51FE-4E42-875A-89D96FD28BDBQ42116864-311E6A7E-7291-4EEE-9DCE-8AB4C50ABED0Q44889813-92A13E14-E11D-459B-AD67-B38A71E71B13Q46799120-A12BFD76-D4A7-436C-9215-526AEF82C0F6Q48264354-7C3D3B88-8EC1-4885-B3FA-1F0604A40DDEQ58793927-B6FC84AA-0566-47F5-A81C-BAEED660331C
P2860
Characterisation of the gene encoding type II DNA topoisomerase from Leishmania donovani: a key molecular target in antileishmanial therapy
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Characterisation of the gene e ...... get in antileishmanial therapy
@ast
Characterisation of the gene e ...... get in antileishmanial therapy
@en
type
label
Characterisation of the gene e ...... get in antileishmanial therapy
@ast
Characterisation of the gene e ...... get in antileishmanial therapy
@en
prefLabel
Characterisation of the gene e ...... get in antileishmanial therapy
@ast
Characterisation of the gene e ...... get in antileishmanial therapy
@en
P2093
P2860
P356
P1476
Characterisation of the gene e ...... get in antileishmanial therapy
@en
P2093
A Dasgupta
H K Majumder
S Bandopadhyay
T Sengupta
P2860
P304
P356
10.1093/NAR/29.9.1844
P407
P577
2001-05-01T00:00:00Z